Palisade Bio, Inc. (NASDAQ:PALI) Given Average Rating of “Buy” by Brokerages

Posted by Stanley Muller on Jul 20th, 2026

Shares of Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report) have been assigned an average recommendation of “Buy” from the nine research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $8.8333.

A number of equities research analysts have recently issued reports on the company. Weiss Ratings lowered Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th. LADENBURG THALM/SH SH raised shares of Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Oppenheimer set a $7.00 price target on shares of Palisade Bio in a research report on Tuesday, June 30th. Wall Street Zen lowered shares of Palisade Bio from a “hold” rating to a “sell” rating in a research note on Monday, July 13th. Finally, Wolfe Research began coverage on shares of Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price objective on the stock.

Read Our Latest Analysis on Palisade Bio

Insider Activity

In other Palisade Bio news, Director Robert Jr. Baltera purchased 25,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were purchased at an average cost of $1.96 per share, with a total value of $49,000.00. Following the completion of the transaction, the director owned 461,904 shares of the company’s stock, valued at approximately $905,331.84. This represents a 5.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mitchell Lawrence Jones sold 51,880 shares of the stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $2.05, for a total value of $106,354.00. Following the completion of the sale, the insider directly owned 94,009 shares of the company’s stock, valued at approximately $192,718.45. This represents a 35.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders acquired 125,000 shares of company stock worth $250,100 over the last quarter. Corporate insiders own 0.07% of the company’s stock.

Hedge Funds Weigh In On Palisade Bio

Several institutional investors and hedge funds have recently bought and sold shares of PALI. XTX Topco Ltd boosted its holdings in shares of Palisade Bio by 53.8% during the fourth quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock worth $51,000 after purchasing an additional 7,584 shares during the period. Cetera Investment Advisers acquired a new position in Palisade Bio in the 4th quarter valued at approximately $25,000. Schonfeld Strategic Advisors LLC acquired a new position in Palisade Bio in the 4th quarter valued at approximately $26,000. Virtu Financial LLC purchased a new stake in Palisade Bio in the 4th quarter worth approximately $28,000. Finally, Atom Investors LP purchased a new stake in Palisade Bio in the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Palisade Bio Price Performance

Shares of PALI opened at $1.97 on Monday. The firm has a 50-day moving average price of $1.92 and a 200 day moving average price of $1.91. The firm has a market capitalization of $341.95 million, a PE ratio of -1.95 and a beta of 1.50. Palisade Bio has a 52-week low of $0.53 and a 52-week high of $2.85.

Palisade Bio (NASDAQ:PALI – Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, equities analysts expect that Palisade Bio will post -0.25 EPS for the current year.

About Palisade Bio

(Get Free Report)

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.